Long-term suppression of hyperparathyroidism by phosphate binders in uremic children.
Forty-five children with stable chronic renal failure, not on dialysis, were treated conservatively with a regimen of mild dietary phosphate restriction and high-dose phosphate binders for up to 5 years. Both aluminum hydroxide and calcium carbonate were used initially, but almost all patients were taking calcium carbonate towards the end of the period. Serum immunoreactive parathyroid hormone concentrations were significantly decreased and were within the normal range after 1 year and remained normal during treatment. There was no significant change in renal function over the same treatment period. We conclude that calcium carbonate should be used as the phosphate binder of choice in the long-term suppression of hyperphosphatemia and hyperparathyroidism in uremic children.
Tamanaha
K
K
Evelina Children's Hospital, United Medical School of Guy, London, UK.
Mak
R H
RH
Rigden
S P
SP
Turner
C
C
Start
K M
KM
Haycock
G B
GB
Chantler
C
C
D000293:Adolescent; D002119:Calcium Carbonate / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy*; D007223:Infant; D007231:Infant, Newborn; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D010710:Phosphates / Q000378:metabolism*
D010710:Phosphates; D002119:Calcium Carbonate